Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice.

Cimen, Ismail; Natarelli, Lucia; Abedi Kichi, Zahra; Henderson, James M; Farina, Floriana M; Briem, Eva; Aslani, Maria; Megens, Remco T A; Jansen, Yvonne; Mann-Fallenbuchel, Elizabeth; Gencer, Selin; Duchêne, Johan; Nazari-Jahantigh, Maliheh; van der Vorst, Emiel P C; Enard, Wolfgang; Döring, Yvonne; Schober, Andreas; Santovito, Donato; Weber, Christian (2023). Targeting a cell-specific microRNA repressor of CXCR4 ameliorates atherosclerosis in mice. Science translational medicine, 15(720), eadf3357. American Association for the Advancement of Science 10.1126/scitranslmed.adf3357

Text scitranslmed.adf3357.pdf - Published Version Restricted to registered users only Available under License Publisher holds Copyright. Download (2MB) | Request a copy

The CXC chemokine receptor 4 (CXCR4) in endothelial cells (ECs) and vascular smooth muscle cells (VSMCs) is crucial for vascular integrity. The atheroprotective functions of CXCR4 in vascular cells may be counteracted by atherogenic functions in other nonvascular cell types. Thus, strategies for cell-specifically augmenting CXCR4 function in vascular cells are crucial if this receptor is to be useful as a therapeutic target in treating atherosclerosis and other vascular disorders. Here, we identified miR-206-3p as a vascular-specific CXCR4 repressor and exploited a target-site blocker (CXCR4-TSB) that disrupted the interaction of miR-206-3p with CXCR4 in vitro and in vivo. In vitro, CXCR4-TSB enhanced CXCR4 expression in human and murine ECs and VSMCs to modulate cell viability, proliferation, and migration. Systemic administration of CXCR4-TSB in Apoe-deficient mice enhanced Cxcr4 expression in ECs and VSMCs in the walls of blood vessels, reduced vascular permeability and monocyte adhesion to endothelium, and attenuated the development of diet-induced atherosclerosis. CXCR4-TSB also increased CXCR4 expression in B cells, corroborating its atheroprotective role in this cell type. Analyses of human atherosclerotic plaque specimens revealed a decrease in CXCR4 and an increase in miR-206-3p expression in advanced compared with early lesions, supporting a role for the miR-206-3p-CXCR4 interaction in human disease. Disrupting the miR-206-3p-CXCR4 interaction in a cell-specific manner with target-site blockers is a potential therapeutic approach that could be used to treat atherosclerosis and other vascular diseases.

Interest & Impact

Downloads

0 since deposited on 06 Nov 2023
0 in the past 12 months

Citations

5 Citations in Web of Science ®
6 Citations in Scopus

Search

in Google Scholar™

Services

Actions (login required)

Edit item

Actions (login required)

Edit item